Expert Reviews Alternative Treatment Options in Muscle-Invasive Bladder Cancer


Shilpa Gupta, MD, shares the current standard of care for muscle-invasive bladder cancer and highlights other options that may be suitable for some patients.

Neoadjuvant cisplatin-based chemotherapy and radical cystectomy is the current standard of care for patients with muscle-invasive bladder cancer, although other options could be a good choice for certain patients, according to Shilpa Gupta, MD.

Gupta, a genitourinary oncologist from Case Comprehensive Cancer Center, spoke with CancerNetwork® during the 2023 Genitourinary Cancers Symposium about the importance of bladder preservation in younger patients. Although transurethral resection of bladder tumor (TURBT), concurrent chemotherapy, and radiation was once a regimen reserved for older patients who weren’t good candidates for surgery, the regimen should also be considered in younger patients.

She also discussed the best regimen for patients who are cisplatin ineligible, including unfit patients. Importantly, she emphasized that surgery may not be the best option for unfit patients who have a poor physical performance status.


The current standard [of care] for muscle-invasive bladder cancer is neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Since our patient population has a median age of 71 [years old], many patients may not be fit for cystectomy.

If they have tumors that are smaller, there is no hydronephrosis, and no widespread carcinoma in-situ, tri-modality therapy with maximal TURBT, concurrent chemotherapy, and radiation is another valid option. In the past, this used to be reserved for patients who are unfit for surgery or are older and not going to tolerate the surgery well but nowadays, a lot of younger patients are also interested in preserving their bladders.

They ask us about this option up front. For patients who are not eligible to receive cisplatin-based chemotherapy due to chronic kidney disease, hearing loss, heart failure, neuropathy, or just poor physical performance status for them, ideally, the up-front cystectomy is the option. [However], if they are overall in poor shape, then again, surgery may not be the best option.

It all depends on the patient's performance status.

Related Videos
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Related Content